Skip to main content
TipRanks
Go Ultimate75% OFF

SAB Biotherapeutics (SABS) Q3 2026 Earnings Report

331 Followers

SABS Q3 2026 EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.28
Beat/Miss
Beat by +$0.04
One Year Ago EPS
-$0.21

SABS Q3 2026 Revenue Results

Actual Revenue
$0
Expected Revenue
$0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
SABS Upcoming Earnings

SAB Biotherapeutics's next earnings date is estimated for April 1, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

SABS Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-11.64%|
Earnings Call Sentiment|Positive

The call was predominantly positive, with strong SAFEGUARD enrollment progress, a consistent safety profile, FDA Fast Track designation, high interest in the PRISE study, and sufficient projected cash runway through 2028. The primary negatives were increased operating expenses, a shift from prior-year net income to a net loss, limited visibility into PRISE timing and redosing data, and the continued uncertainty that Fast Track does not guarantee approval.

Company Guidance

SAB BIO is reaffirming its guidance to complete enrollment of SAFEGUARD in Q4, with topline data expected in the second half of '27; the PRISE study expects to dose the first patients this quarter, with 7 clinical sites planned across the United States, Europe and the UK. The company projects that its existing cash balance will fund its operations through 2028, and said the burn as guided has accounted for the PRISE expenses and doesn't change. SAB BIO is not guiding to a specific time for PRISE data yet, but would expect it to be subsequent to SAFEGUARD data.

  • SAFEGUARD Enrollment ProgressThe adult and adolescent cohorts in the registrational Phase 2b SAFEGUARD study are fully enrolled and closed for screening. The Data Monitoring Committee approved the final step-down to children ages 5 to 11 in September, and the company reaffirmed guidance to complete enrollment in Q4 2026, with topline data expected in the second half of 2027.
  • Fast Track Designation for SAB-142The FDA granted Fast Track designation to SAB-142 in October 2026 for treatment of new-onset Stage 3 type 1 diabetes. The designation provides opportunities for more frequent FDA meetings and written communications, eligibility for rolling review of a future BLA, and potential eligibility for Priority Review if applicable criteria are met.
  • PRISE Study Expansion OpportunityThe investigator-led Phase 3 PRISE study expects to dose its first patients in the quarter. The study plans to enroll across 7 clinical sites in the United States, Europe, and the UK, with cohorts covering patients within 100 days, 100 to 365 days, and 1 to 2 years from Stage 3 diagnosis. The study is intended to support a potential future label expansion for patients up to 2 years from diagnosis.
  • Strong Physician and Patient InterestManagement reported very high physician interest and strong demand for PRISE, citing inbound interest from the type 1 diabetes and academic communities. The company said there is substantial demand from patients and physicians seeking treatment options beyond the current dosing windows for immunomodulatory therapies.
  • Consistent Safety Profile Across Age GroupsThe independent Data Monitoring Committee reviewed unblinded cumulative safety data across treatment arms and age groups and approved the planned pediatric step-down without delays. Management stated that no new safety signal was identified and that SAB-142 demonstrated a consistent safety profile across adults, adolescents, and pediatric patients.
  • Baseline Characteristics Remain ConsistentBaseline characteristics for the fully enrolled adult and adolescent SAFEGUARD cohorts were described as comparable to the respective age cohorts in prior TN-19 and MELD-ATG trials.
  • Cash Runway and FundingSAB BIO ended the quarter with $205 million in cash, cash equivalents, and investment securities as of September 30, 2026, and projects that its existing cash balance will fund operations through 2028. The company also received $13.4 million in gross proceeds during the quarter from the exercise of previously issued enrollment and data release warrants.
  • Continued Investment in SAB-142 DevelopmentThe company reaffirmed its ability to support SAB-142 clinical development in the SAFEGUARD and PRISE studies through key milestones while preparing for commercial readiness. Management said the PRISE study was already included in the budgeting process and did not change the guided cash burn.
  • Potential Differentiation Through Fully Human DesignManagement stated that SAB-142's fully human antibody design may provide lower immunogenicity than non-human approaches, with the potential for redosing over a longer period. Topline data are expected to include immunogenicity and safety data associated with long-term redosing, along with beta-cell preservation, HbA1c, and continuous glucose monitoring results.
  • Clinical Endpoint and Regulatory PathwayThe primary endpoint is preservation of beta-cell function measured by area under the curve C-peptide. Management stated that statistically significant results versus the control arm would provide an accelerated path to approval, while glycemic-control data based on HbA1c and continuous glucose monitoring will also be reported.
  • Positive Field Validation From Tzield UptakeManagement said it is encouraged by Tzield's uptake in the community, viewing the adoption of a new therapy for preserving pancreatic function as evidence of physician and patient interest in disease-modifying treatment. SAB-142 is positioned as potentially competitive with fewer days of dosing, subject to its future efficacy results.
  • Potential Expansion of the Treatable PopulationManagement stated that, subject to positive PRISE results, treatment eligibility could potentially be based more on the amount of remaining beta cells than solely on time from diagnosis, or could potentially extend to up to 2 years from diagnosis. The company said this would markedly expand the available total addressable market and could increase market penetration.

SABS Earnings History

SABS earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Apr 01, 20272026 (Q4)-0.24--0.35――
Nov 05, 20262026 (Q3)-0.28-0.24-0.21-14.29% (-0.03)
Aug 06, 20262026 (Q2)-0.29-0.28-1.0974.31% (+0.81)
May 12, 20262026 (Q1)-0.21-0.35-0.5637.50% (+0.21)
Mar 26, 20262025 (Q4)-0.21-0.27-1.2378.05% (+0.96)
Nov 13, 20252025 (Q3)-0.46-0.21-1.1281.25% (+0.91)
Aug 07, 20252025 (Q2)-0.80-1.09-0.79-37.97% (-0.30)
May 09, 20252025 (Q1)―--0.54―
Mar 31, 20252024 (Q4)-1.07-0.56-0.54-3.70% (-0.02)
Nov 06, 20242024 (Q3)-1.11-1.12-1-12.00% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed